Incidence of alloantibody formation after ABO-D or extended matched red blood cell transfusions: A randomized trial (MATCH study)

Transfusion

Volumn 56, Issue 2, 2016, Pages 311-320

  Schonewille, Henk ^a,b   Honohan, Áine ^a,b   Van Der Watering, Leo M G ^a,b   Hudig, Francisca ^c   Te Boekhorst, Peter A ^d   Koopman Van Gemert, Ankie W M M ^e   Brand, Anneke ^b  

^a SANQUIN RESEARCH   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c HAGA HOSPITAL   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e ALBERT SCHWEITZER HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; ALLOANTIGEN; ERYTHROCYTE ANTIBODY; BLOOD GROUP RHESUS SYSTEM; RHO(D) ANTIGEN;

ADULT; AGED; ALLOIMMUNIZATION; ANTIBODY PRODUCTION; ARTICLE; BLOOD GROUP ABO SYSTEM; BLOOD GROUP TYPING; CONTROLLED STUDY; ERYTHROCYTE; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SURGICAL PATIENT; THROMBOCYTE TRANSFUSION; ADVERSE EFFECTS; BLOOD; BLOOD GROUP RHESUS SYSTEM; CLINICAL TRIAL; IMMUNOLOGY; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; ISOANTIBODIES; MALE; MIDDLE AGED; RH-HR BLOOD-GROUP SYSTEM;

EID: 84958844529     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13347     Document Type: Article

References (35)

1. Bauer MP, Wiersum-Osselton J, Schipperus M, et al., Clinical predictors of alloimmunization after red blood cell transfusion. Transfusion 2007; 47: 2066-71.
2. Zalpuri S, Zwaginga JJ, le Cessie S, et al., Red-blood-cell alloimmunization and number of red-blood-cell transfusions. Vox Sang 2012; 102: 144-9.
3. Sanz C, Nomdedeu M, Belkaid M, et al., Red blood cell alloimmunization in transfused patients with myelodysplastic syndrome or chronic myelomonocytic leukemia. Transfusion 2013; 53: 710-5.
4. Zalpuri S, Evers D, Zwaginga JJ, et al., Immunosuppressants and alloimmunization against red blood cell transfusions. Transfusion 2014; 54: 1981-7.
5. Schonewille H, Doxiadis II, Levering WH, et al., HLA-DRB1 associations in individuals with single and multiple clinically relevant red blood cell antibodies. Transfusion 2014; 54: 1971-80.
6. Tormey CA, Fisk J, Stack G., Red blood cell alloantibody frequency, specificity, and properties in a population of male military veterans. Transfusion 2008; 48: 2069-76.
7. van de Watering L, Hermans J, Witvliet M, et al., HLA and RBC immunization after filtered and buffy coat-depleted blood transfusion in cardiac surgery: a randomised controlled trial. Transfusion 2003; 43: 765-71.
8. Schonewille H, van de Watering LM, Brand A., Additional red blood cell alloantibodies after blood transfusions in a nonhematologic alloimmunized patient cohort: is it time to take precautionary measures? Transfusion 2006; 46: 630-5.
9. Schonewille H, Klumper FJ, van de Watering LM, et al., High additional maternal red cell alloimmunization after Rhesus- and K-matched intrauterine intravascular transfusions for hemolytic disease of the fetus. Am J Obstet Gynecol 2007; 196: 143.e1-6.
10. Schonewille H, de Vries RR, Brand A., Alloimmune response after additional red blood cell antigen challenge in immunized hematooncology patients. Transfusion 2009; 49: 453-7.
11. Rosse WF, Gallagher D, Kinney TR, et al., Transfusion and alloimmunization in sickle cell disease. The Cooperative Study of Sickle Cell Disease. Blood 1990; 76: 1431 -7.
12. Vichinsky EP, Luban NL, Wright E, et al., Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion 2001; 41: 1086-9 2.
13. LaSalle-Williams M, Nuss R, Le T, et al., Extended red blood cell antigen matching for transfusions in sickle cell disease: a review of a 14-year experience from a single center (CME). Transfusion 2011; 51: 1732-9.
14. Miller ST, Kim HY, Weiner DL, et al., Red blood cell alloimmunization in sickle cell disease: prevalence in 2010. Transfusion 2013; 53: 704-9.
15. Chou ST, Jackson T, Vege S, et al., High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood 2013; 122: 1062-71.
16. Goldman M, Lane D, Webert K, et al., The prevalence of anti-K in Canadian prenatal patients. Transfusion 2015; 55: 1486-91.
17. English translation of the Dutch blood transfusion guideline 2011 [Internet]. Amsterdam: ISBT Central Office; 2012 [cited July 2014]. Available from: http://www.diliguide.nl/document/7584
18. Schonewille H, van de Watering LM, Loomans DS, et al., Red blood cell alloantibodies after transfusion: factors influencing incidence and specificity. Transfusion 2006; 46: 250-6.
19. Redman M, Regan F, Contreras M., A prospective study of the incidence of red cell allo-immunisation following transfusion. Vox Sang 1996; 71: 216-20.
20. Alves VM, Martins PR, Soares S, et al., Alloimmunization screening after transfusion of red blood cells in a prospective study. Rev Bras Hematol Hemoter 2012; 34: 206-11.
21. Elebute MO, Choo L, Mora A, et al., Transfusion of prion-filtered red cells does not increase the rate of alloimmunization or transfusion reactions in patients: results of the UK trial of prion-filtered versus standard red cells in surgical patients (PRISM A). Br J Haematol 2013; 160: 701-8.
22. Schonewille H, Brand A., Alloimmunization to red blood cell antigens after universal leucodepletion. A regional multicentre retrospective study. Br J Haematol 2005; 129: 151-6.
23. Winters JL, Richa EM, Bryant SC, et al., Polyethylene glycol antiglobulin tube versus gel microcolumn: influence on the incidence of delayed hemolytic transfusion reactions and delayed serologic transfusion reactions. Transfusion 2010; 50: 1444-52.
24. Schultz KF, Altman DG, Moher D, et al. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol 2010; 63: 834-40.
25. Ramsey G, Smietana SJ., Long-term follow-up testing of red cell alloantibodies. Transfusion 1994; 34: 122-4.
26. Schonewille H, Haak HL, van Zijl AM., RBC antibody persistence. Transfusion 2000; 40: 1127-31.
27. Reverberi R., The persistence of red cell alloantibodies. Blood Transfus 2008; 6: 225-34.
28. Tormey CA, Stack G., The persistence and evanescence of blood group alloantibodies in men. Transfusion 2009; 49: 505-12.
29. Hogervorst E, Middelburg R, Brand A, et al., Anti-K formation is not associated with the storage time of transfused red blood cells. Transfusion 2015; 55(6 Pt 2): 1472-7.
30. Atoyebi W, Mundy N, Croxton T, et al., Is it necessary to administer anti-D to prevent RhD immunization after the transfusion of RhD-positive platelet concentrates? Br J Haematol 2000; 111: 980-3.
31. Cid J, Carbassé G, Pereira A, et al., Platelet transfusions from D+ donors to D- patients: a 10-year follow-up study of 1014 patients. Transfusion 2011; 51: 1163-9.
32. O'Brien K, Haspel RL, Uhl L., Anti-D alloimmunisation after D-incompatible platelet transfusions: a 14-year single-institution retrospective review. Transfusion 2014; 54: 650-4.
33. Kitazawa J, Nollet K, Morioka H, et al., Non-D Rh antibodies appearing after apheresis platelet transfusion: stimulation by red cells or microparticles? Vox Sang 2011; 100: 395-400.
34. Moncharmont P, Barday G, Meyer F., Red blood cell alloimmunisation after platelet transfusion: a 5-year study. Blood Transfus 2014; 12Suppl1: s147-8.
35. Moncharmont P, Barday G, Meyer F., Red blood cell alloimmunisation in 18 to 50-year old transfused women: a 3-year study. Blood Transfus 2015; 13: 345-6.